| 86 | Parkinson disease |
| 69 | Humans |
| 67 | Nervous system diseases |
| 37 | Male |
| 33 | Human |
| 31 | Female |
| 29 | Middle Aged |
| 28 | Aged |
| 19 | Parkinson's disease |
| 19 | Adult |
| 16 | Parkinson Disease (genetics) |
| 16 | Animals |
| 14 | Deep brain stimulation |
| 13 | Parkinson Disease (diagnosis) |
| 11 | Phenotype |
| 11 | Parkinson Disease (physiopathology) |
| 10 | Parkinson Disease (therapy) |
| 9 | Parkinsonism |
| 9 | Aged, 80 and over |
| 8 | Risk factor |
| 8 | Mutation |
| 7 | deep brain stimulation |
| 7 | Subthalamic nucleus |
| 7 | Parkin |
| 7 | Case-Control Studies |
| 6 | Treatment Outcome |
| 6 | Severity of Illness Index |
| 6 | Protein-Serine-Threonine Kinases (genetics) |
| 6 | Parkinson Disease (psychology) |
| 6 | Parkinson Disease (epidemiology) |
| 6 | Mice |
| 6 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 6 | Emission tomography |
| 6 | Electroencephalography |
| 6 | Diagnosis |
| 6 | Deep Brain Stimulation |
| 6 | Cohort Studies |
| 5 | genetics |
| 5 | Prospective Studies |
| 5 | Parkinson Disease (drug therapy) |
| 5 | Parkinson Disease (complications) |
| 5 | Genetic disease |
| 5 | Dopamine |
| 5 | Basal ganglion |
| 5 | Antiparkinson Agents (therapeutic use) |
| 4 | Time Factors |
| 4 | Risk Factors |
| 4 | Receptors, Dopamine D2 (metabolism) |
| 4 | Quality of Life |
| 4 | Positron emission tomography |
| 4 | Photon |
| 4 | Parkinson Disease (pathology) |
| 4 | Nuclear magnetic resonance imaging |
| 4 | Multicenter study |
| 4 | Medical screening |
| 4 | Levodopa |
| 4 | Levodopa (therapeutic use) |
| 4 | Genotype |
| 4 | Genome-Wide Association Study |
| 4 | Genetic determinism |
| 4 | Genetic Predisposition to Disease |
| 4 | Follow-Up Studies |
| 4 | Familial disease |
| 4 | Executive function |
| 4 | Dystonia |
| 4 | Comparative study |
| 4 | Age of onset |
| 3 | subthalamic nucleus |
| 3 | parkinsonism |
| 3 | movement disorders |
| 3 | dystonia |
| 3 | dopamine |
| 3 | Surveys and Questionnaires |
| 3 | Subthalamic Nucleus (physiology) |
| 3 | Safety |
| 3 | Reproducibility of Results |
| 3 | Rat |
| 3 | Psychiatric Status Rating Scales |
| 3 | Protein Transport |
| 3 | Prognosis |
| 3 | Positron-Emission Tomography |
| 3 | Pathogenesis |
| 3 | Parkinson Disease (etiology) |
| 3 | Neuropsychological Tests |
| 3 | Neurons (physiology) |
| 3 | Mutation, Missense |
| 3 | Mutation (genetics) |
| 3 | Multiple System Atrophy (diagnosis) |
| 3 | Motor Cortex (physiopathology) |
| 3 | Long term |
| 3 | Locus |
| 3 | Linkage |
| 3 | Impulse control disorder |
| 3 | Idiopathic |
| 3 | Genetics |
| 3 | Field potential |
| 3 | Exploration |
| 3 | Epidemiology |
| 3 | Environment |
| 3 | Encephalon |
| 3 | Emotion emotionality |
| 3 | Double-Blind Method |
| 3 | Dopamine (metabolism) |
| 3 | Disease Models, Animal |
| 3 | Dementia |
| 3 | Cross-Sectional Studies |
| 3 | Cross sectional study |
| 3 | Computational Biology |
| 3 | Clinical management |
| 3 | Brain (metabolism) |
| 3 | Biomarkers (cerebrospinal fluid) |
| 3 | Association |
| 3 | Analysis of Variance |
| 2 | tau Proteins (cerebrospinal fluid) |
| 2 | systematic review |
| 2 | submillimetre: galaxies |
| 2 | stars: neutron |
| 2 | rating scales |
| 2 | programming |
| 2 | motor fluctuations |
| 2 | methods: statistical |
| 2 | methods: numerical |
| 2 | meta‐analysis |
| 2 | gene‐environment interaction |
| 2 | galaxies: formation |
| 2 | dark matter |
| 2 | clinimetrics |
| 2 | classification |
| 2 | angling |
| 2 | angler |
| 2 | alpha-Synuclein (genetics) |
| 2 | alpha-Synuclein (cerebrospinal fluid) |
| 2 | VTA |
| 2 | Ubiquitin-Protein Ligases (genetics) |
| 2 | Treatment |
| 2 | Technique |
| 2 | Symptomatology |
| 2 | Stimulation |
| 2 | Speech |
| 2 | Speech Perception (physiology) |
| 2 | Societies, Scientific (standards) |
| 2 | Single photon emission tomography |
| 2 | Sibling |
| 2 | Sequence Homology, Amino Acid |
| 2 | Sensitivity and Specificity |
| 2 | Senescence |
| 2 | Revision |
| 2 | Review |
| 2 | Regression Analysis |
| 2 | Reference Standards |
| 2 | Rats |
| 2 | REM Sleep Behavior Disorder (epidemiology) |
| 2 | REM Sleep Behavior Disorder (diagnosis) |
| 2 | Quality of life |
| 2 | Quality of Life (psychology) |
| 2 | Putamen |
| 2 | Protozoan Proteins (metabolism) |
| 2 | Protein Kinases (genetics) |
| 2 | Prosody |
| 2 | Programming |
| 2 | Predictive Value of Tests |
| 2 | Practice Guidelines as Topic (standards) |
| 2 | Postoperative |
| 2 | Positron |
| 2 | Polymorphism, Single Nucleotide (genetics) |
| 2 | Phylogeny |
| 2 | Pesticides |
| 2 | Pedigree |
| 2 | Parkinson Disease (surgery) |
| 2 | Parkinson Disease (metabolism) |
| 2 | Parkinson Disease (cerebrospinal fluid) |
| 2 | Paraquat |
| 2 | PET |
| 2 | Optimization |
| 2 | Neurons (metabolism) |
| 2 | Neural Pathways (drug effects) |
| 2 | Myelodysplastic syndrome |
| 2 | Mutation (physiology) |
| 2 | Multiple system atrophy |
| 2 | Multiple System Atrophy (cerebrospinal fluid) |
| 2 | Movement (physiology) |
| 2 | Motor system disorder |
| 2 | Motor cortex |
| 2 | Motor Cortex (drug effects) |
| 2 | Mood Disorders (etiology) |
| 2 | Midbrain |
| 2 | Mice, Knockout |
| 2 | Mice, Inbred C57BL |
| 2 | Memory disorder |
| 2 | Medicine |
| 2 | Longitudinal Studies |
| 2 | Locus niger |
| 2 | Lewy body |
| 2 | Lewy body disease |
| 2 | Lewy body dementia |
| 2 | Lewy Body Disease (genetics) |
| 2 | Lesion |
| 2 | Language |
| 2 | International Cooperation |
| 2 | Interaction |
| 2 | Image Processing, Computer-Assisted |
| 2 | Heterozygote |
| 2 | Herbicide |
| 2 | Haplotype |
| 2 | Green Fluorescent Proteins (metabolism) |
| 2 | Germany |
| 2 | Genetic linkage |
| 2 | Genetic Loci (genetics) |
| 2 | Genetic Linkage (genetics) |
| 2 | Genetic Association Studies |
| 2 | Galaxy: formation |
| 2 | Functional Laterality (physiology) |
| 2 | Fluctuations |
| 2 | Family study |
| 2 | Evaluation scale |
| 2 | Emotions (physiology) |
| 2 | Electroencephalography (methods) |
| 2 | Electrocardiography |
| 2 | Electric Stimulation |
| 2 | Elderly |
| 2 | Dystonic Disorders (genetics) |
| 2 | Drug Combinations |
| 2 | Double blind study |
| 2 | Dopaminergic neuron |
| 2 | Dopamine agonist |
| 2 | Dopamine Plasma Membrane Transport Proteins (metabolism) |
| 2 | Dopamine Agonists (pharmacology) |
| 2 | Disease Progression |
| 2 | Disability Evaluation |
| 2 | Depression |
| 2 | Deep Brain Stimulation (methods) |
| 2 | DNA Mutational Analysis |
| 2 | Corpus striatum |
| 2 | Corpus Striatum (metabolism) |
| 2 | Compensation |
| 2 | Chromosome A2 |
| 2 | Child |
| 2 | Cerebrovascular disease |
| 2 | Cerebrospinal fluid |
| 2 | Case study |
| 2 | Case control study |
| 2 | Cartography |
| 2 | Carrier |
| 2 | Caregivers (psychology) |
| 2 | Cardiovascular disease |
| 2 | Carbon Radioisotopes |
| 2 | Calcium Channels, T-Type (metabolism) |
| 2 | Calcium Channels, T-Type (genetics) |
| 2 | Calcium Channel Blockers (pharmacology) |
| 2 | Brain (diagnostic imaging) |
| 2 | Biomarkers |
| 2 | Behavior |
| 2 | Base Sequence |
| 2 | Autosomal character |
| 2 | Apolipoproteins E (genetics) |
| 2 | Anatomic pathology |
| 2 | Alzheimer Disease (genetics) |
| 2 | Alzheimer Disease (diagnosis) |
| 2 | Alzheimer Disease (cerebrospinal fluid) |
| 2 | Algorithm |
| 2 | Agriculture |
| 2 | Age Factors |
| 1 | β-Glucosidase |
| 1 | áreas protegidas |
| 1 | yellowfish |
| 1 | westslope cutthroat trout |
| 1 | wearing‐off |
| 1 | wavelet transform |
| 1 | ventricular tachycardia |
| 1 | ventricular late potentials |
| 1 | ventricular fibrillation |
| 1 | trunk flexion |
| 1 | trunk extension |
| 1 | trucha |
| 1 | trk receptor |
| 1 | treatment |
| 1 | treatment, clinical trial |
| 1 | translational |
| 1 | tics |
| 1 | tauopathies |
| 1 | taimen |
| 1 | systemic suppression |
| 1 | sustainable fisheries management |
| 1 | sustainability |
| 1 | substance abuse |
| 1 | stroke |
| 1 | striatum |
| 1 | stakeholders |
| 1 | specificity |
| 1 | signal-averaged ECG |
| 1 | sequencing |
| 1 | sensitivity |
| 1 | schizophrenia |
| 1 | scanning probe microscopy |
| 1 | salmón del Atlántico |
| 1 | safety |
| 1 | sPD = sporadic Parkinson's disease |
| 1 | rockfish |
| 1 | reporting recommendations |
| 1 | rehabilitation |
| 1 | reevaluation |
| 1 | recurrent mutations |
| 1 | recreational fishing |
| 1 | questionnaire |
| 1 | quality of life |
| 1 | pulsars: general |
| 1 | publication guidelines |
| 1 | psychosis |
| 1 | psychosis biomarker |
| 1 | progressive supranuclear palsy |
| 1 | prevention |
| 1 | prediction |
| 1 | pramipexole |
| 1 | postoperative management |
| 1 | positron emission tomography |
| 1 | polycycles |
| 1 | photoelectron spectroscopy |
| 1 | phosphate |
| 1 | phenocopy |
| 1 | phencyclidine |
| 1 | pharmacogenomics |
| 1 | phantosmias |
| 1 | pez roca |
| 1 | pesticide |
| 1 | pescadores de caña |
| 1 | pesca recreativa |
| 1 | peroxynitrite |
| 1 | perampanel |
| 1 | pathophysiology |
| 1 | partes interesadas |
| 1 | parkin |
| 1 | paraquat |
| 1 | parameter |
| 1 | palaeoceanography |
| 1 | pain |
| 1 | p120RasGAP |
| 1 | outcome |
| 1 | orobulbar features |
| 1 | origin |
| 1 | onset age |
| 1 | oligodendrocytes |
| 1 | olfaction |
| 1 | non‐motor |
| 1 | nitrogen heterocycles |
| 1 | neuroimaging |
| 1 | neuroacanthocytosis |
| 1 | myoclonus‐dystonia |
| 1 | mycorrhiza |
| 1 | multiresolution decomposition |
| 1 | multiplex ligation‐dependent probe amplification |
| 1 | multiple system atrophy |
| 1 | multiple sclerosis |
| 1 | mtDNA |
| 1 | mitochondria |
| 1 | migraine without aura |
| 1 | microtubule‐associated protein tau |
| 1 | methods: N‐body simulations |
| 1 | maternal inheritance |
| 1 | marine protected areas |
| 1 | malformation |
| 1 | maintenance |
| 1 | linkage disequilibrium |
| 1 | linkage analysis |
| 1 | levodopa |
| 1 | intraspecific gene flow |
| 1 | intergalactic medium |
| 1 | infrared: galaxies |
| 1 | imidazolinones |
| 1 | imaging |
| 1 | hydrogen bonds |
| 1 | heterozygous changes |
| 1 | heteroplasmy |
| 1 | hereditary hemorrhagic telangiectasia |
| 1 | hereditary benign telangiectasia |
| 1 | herbicide tolerance |
| 1 | heart failure |
| 1 | head drops |
| 1 | guidelines |
| 1 | gran barrera arrecifal |
| 1 | glutathione transferase |
| 1 | glutamate antagonists |
| 1 | glomales |
| 1 | globus pallidus |
| 1 | globus pallidus internus |
| 1 | genome‐wide association |
| 1 | gene‐disease associations |
| 1 | genetic testing |
| 1 | genetic risk factors |
| 1 | gene mutations |
| 1 | gene knockouts |
| 1 | gamma‐rays: bursts |
| 1 | gambling |
| 1 | galaxies: structure |
| 1 | galaxies: statistics |
| 1 | galaxies: individual: NGC 1275 |
| 1 | galaxies: high‐redshift |
| 1 | galaxies: haloes |
| 1 | galaxies: dwarf |
| 1 | galaxies: clusters: general |
| 1 | frontotemporal dementia with parkinsonism linked to chromosome 17 |
| 1 | frontopolar |
| 1 | fisheries management |
| 1 | fish welfare |
| 1 | feedback‐learning |
| 1 | exon rearrangements |
| 1 | ethics |
| 1 | epidemiology |
| 1 | efficacy |
| 1 | dyskinesias |
| 1 | dronedarone |
| 1 | dopa‐responsive dystonia |
| 1 | dopamine supersensitivity |
| 1 | dopamine receptors |
| 1 | dopamine agonist |
| 1 | distribution |
| 1 | dioxins |
| 1 | dibenzofurans |
| 1 | developmental abnormalities |
| 1 | density functional calculations |
| 1 | degenerative brain |
| 1 | damtjernite |
| 1 | cyclohexenone derivative |
| 1 | cutthroat trout |
| 1 | cruelty |
| 1 | corticobasal degeneration |
| 1 | cortical dysplasia |
| 1 | conversion |
| 1 | code of conduct |
| 1 | clearfield® production system |
| 1 | chorea‐acanthocytosis |
| 1 | chirality |
| 1 | cell death |
| 1 | celivarone |
| 1 | catheter ablation |
| 1 | carbon and oxygen stable isotopes |
| 1 | capillary |
| 1 | break point analysis |
| 1 | brain asymmetry |
| 1 | biocentrism |
| 1 | behavioral symptoms |
| 1 | basal ganglia |
| 1 | barley |
| 1 | autoregulation |
| 1 | atrial flutter |
| 1 | atrial fibrillation |
| 1 | asthenic build |
| 1 | arteriovenous |
| 1 | arteriovenous fistula |
| 1 | anosmia |
| 1 | animal rights |
| 1 | animal liberation |
| 1 | anglers |
| 1 | amphetamine |
| 1 | amiodarone |
| 1 | alpha-Synuclein (analysis) |
| 1 | alnöite |
| 1 | alkaline rocks |
| 1 | aillikite |
| 1 | acanthocytes |
| 1 | [3H]WIN 35428 |
| 1 | [3H]SCH 23390 |
| 1 | X‐rays: galaxies |
| 1 | Xanthines (therapeutic use) |
| 1 | Xanthines (pharmacology) |
| 1 | X chromosome |
| 1 | World Congress of Psychiatric Genetics |
| 1 | Workplace |
| 1 | Working memory |
| 1 | Woman |
| 1 | Wilhelm von Humboldt |
| 1 | Wear |
| 1 | Walking |
| 1 | WHO |
| 1 | Vitamin deficiency |
| 1 | Vesicular Transport Proteins (genetics) |
| 1 | Vesicular Monoamine Transport Proteins (metabolism) |
| 1 | Verbal perception |
| 1 | Variant |
| 1 | Variance component |
| 1 | Variability |
| 1 | Validation |
| 1 | VMAT2 = vesicular monoamine transporter |
| 1 | Uptake |
| 1 | United States |
| 1 | Unified Parkinson's Disease Rating Scale |
| 1 | Ultrasound |
| 1 | Ubiquitin-Protein Ligases (metabolism) |
| 1 | UPDRS |
| 1 | UPDRS = Unified Parkinson's Disease Rating Scale |
| 1 | Tyrosine 3-Monooxygenase (metabolism) |
| 1 | Two-Hybrid System Techniques |
| 1 | Twin |
| 1 | Tryptophan (blood) |
| 1 | Trifluralin |
| 1 | Tremor |
| 1 | Tremor (therapy) |
| 1 | Tremor (physiopathology) |
| 1 | Tremor (genetics) |
| 1 | Tremor (etiology) |
| 1 | Tremor (complications) |
